Dendritic cell vaccines in the treatment of multiple myeloma: Advances and Limitations

Medical Oncology

Volumn 19, Issue 4, 2002, Pages 213-218

  Büchler, Tomas ^a   Hajek, Roman ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

Cytotoxic T cells; Dendritic cells; Immunotherapy; Multiple myeloma; Tumor immunology

Indexed keywords

CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INHIBITOR OF DIFFERENTIATION PROTEIN; KEYHOLE LIMPET HEMOCYANIN; PROTEIN DERIVATIVE; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DOWN REGULATION; EFFECTOR CELL; ERYTHEMA; FEVER; HUMAN; IMMUNE RESPONSE; INJECTION PAIN; LYMPHOCYTE ACTIVATION; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SKIN INDURATION; SKIN TOXICITY; THROMBOPHLEBITIS; TUMOR CELL; VACCINATION;

CANCER VACCINES; CLINICAL TRIALS; DENDRITIC CELLS; HUMANS; MULTIPLE MYELOMA; VACCINATION;

EID: 0036917785     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:19:4:213     Document Type: Review

References (52)

1. Barlogie, B., Jagannath, S., Vesole, D. and Tricot, G. (1995). Autologous and allogeneic transplants for multiple myeloma. Semin. Hematol. 32:31-44.
2. Lokhorst, H.M., Schattenberg, A., Cornelissen, J.J., Thomas, L.L. and Verdonck, L.F. (1997). Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 90:4206-4211.
3. Hart, D.N. and Hill, G.R. (1999). Dendritic cell immunotherapy for cancer: Application to low-grade lymphoma and multiple myeloma. Immunol. Cell Biol. 77:451-459.
4. Österborg, A., Yi, Q., Henriksson, L., Fagerberg, J. and Bergenbrant, S. (1998). Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses. Blood 91:2459-2466.
5. Wen, Y.J., Barlogie, B. and Yi, Q. (2001). Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: Evidence for their capacity to lyse autologous primary tumor cells. Blood 97:1750-1755.
6. Lim, S.H., Wen, Y.J. and Ling, M. (2000). Malignancy: Idiotypic immune targeting of multiple myeloma. Hematology 4:471-477.
7. Porgador, A. and Gilboa, E. (1995). Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J. Exp. Med. 182:255-260.
8. Steinman, R.M. (1996). Dendritic cells and immune-based therapies. Exp. Hematol. 24:859-862.
9. Marten, A., et al. (2001). Enhanced lytic activity of cytokine-induced killer cells against multiple myeloma cells after co-culture with idiotype-pulsed dendritic cells. Haematologica 86:1029-1037.
10. Timmerman, J.M. and Levy, R. (2000). Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine. J. Immunol. 164:4797-4803.
11. Hart, D.N.J. (1997). Dendritic cells: Unique leukocyte populations which control the primary immune response. Blood 90:3245-3287.
12. O'Doherty, U., et al. (1994). Human blood contains two subsets of dendritic cells, one immunologically mature and the other immature. Immunology 82:487-493.
13. Banchereau, J. and Steinman, R.M. (1998). Dendritic cells and the control of immunity. Nature 392:245-252.
14. Hajek, R. and Butch, A.W. (2000). Dendritic cell biology and the application of dendritic cells to immunotherapy of multiple myeloma. Med. Oncol. 17:2-15.
15. Sallusto, F., Cella, M., Danieli, C. and Lanzavecchia, A. (1995). Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: Downregulation by cytokines and bacterial products. J. Exp. Med. 182:389-400.
16. Brossart, P., Wirths, S., Brugger, W. and Kanz, L. (2001). Dendritic cells in cancer vaccines. Exp. Hematol. 29:1247-1255.
17. Lardon, F., et al. (1997). Generation of dendritic cells from bone marrow progenitors using GM-CSF, TNF-alpha, and additional cytokines: Antagonistic effects of IL-4 and IFN-gamma and selective involvement of TNF-alpha receptor-1. Immunology 91:553-559.
18. Szabolcs, P., et al. (1996). Dendritic cells and macrophages can mature independently from a human bone marrow-derived, post-colony-forming unit intermediate. Blood 87:4520-4530.
19. Caux, C., et al. (1996). CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF alpha. J. Exp. Med. 184:695-706.
20. Bender, A., Sapp, M., Schuler, G., Steinman, R.M. and Bhardwaj, N. (1996). Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J. Immunol. Methods 196:121-135.
21. Romani, N., et al. (1996). Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J. Immunol. Methods 196:137-151.
22. Bernhard, H., et al. (1995). Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood. Cancer Res. 55:1099-1104.
23. Chapuis, F., et al. (1997). Differentiation of human dendritic cells from monocytes in vitro. Eur. J. Immunol. 27:431-441.
24. Hsu, F.J., et al. (1996). Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2:52-58.
25. Kwak, L.W., et al. (1992). Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N. Engl. J. Med. 327:1209-1215.
26. Reichardt, V.L., et al. (1999). Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - A feasibility study. Blood 93:2411-2419.
27. Liso, A., et al. (2000). Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Biol. Blood Marrow Transplant. 6:621-627.
28. Wen, Y.J., Ling, M., Bailey-Wood, R. and Lim, S.H. (1998). Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma. Clin. Cancer Res. 4:957-962.
29. Lim, S.H. and Bailey-Wood, R. (1999). Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma. Int. J. Cancer 83:215-222.
30. Cull, G., Durrant, L., Stainer, C., Haynes, A. and Russell, N. (1999). Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma. Br. J. Haematol. 107:648-655.
31. Titzer, S., et al. (2000). Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: Immunological and clinical aspects. Br. J. Haematol. 108:805-816.
32. Reichardt, V.L., et al. (2000). Specific immunotherapy of multiple myeloma patients using idiotype pulsed serum free generated dendritic cells. Program and Abstracts of the 43rd Annual Meeting of the American Society of Hematology, abstract 1594.
33. Van Rhee, F., et al. (2001). Dendritic cells pulsed with autologous myeloma lysates stimulate myeloma specific cytotoxic T-lymphocytes. Program and Abstracts of the 43rd Annual Meeting of the American Society of Hematology, abstract 1595.
34. Mac Kenzie, M., Strang, G., Peshwa, M., Sopapan, J. and Valone, F. (1998). Phase I/II trial of immunotherapy with idiotype-loaded autologous dendritic cells (APC8020) for refractory multiple myeloma. Blood 92(Suppl. 1), 108a, Abstract 441.
35. Ishisaka, T., Nevin, B., Valone, F.H., Kothari, S.S. and Peshwa, M.V. (2001). Comparison of cryopreserved versus fresh formulation of idiotype-loaded autologous dendritic cell vaccine. Program and Abstracts of the 43rd Annual Meeting of the American Society of Hematology, abstract 4989.
36. Nestle, F.O., et al. (1998). Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4:328-332.
37. Brossart, P., et al. (2000). Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96:3102-3108.
38. Cook, G. and Campbell, J.D. (1999). Immune regulation in multiple myeloma: The host-tumour conflict. Blood Rev. 13:151-162.
39. Yi, Q. (2002). Immunoregulatory mechanisms and immunotherapy, in Myeloma (Mehta, J. and Singhal, S., eds), pp 81-97, Martin Dunitz, London.
40. Schultze, J.L. (1999). Why do B cell lymphoma fail to elicit clinically sufficient T cell immune responses? Leuk. Lymphoma 32:223-236.
41. Frassanito, M.A., Cusmai, A. and Dammacco, F. (2001). Deregulated cytokine network and defective Th1 immune response in multiple myeloma. Clin. Exp. Immunol. 125:190-197.
42. Raje, N., et al. (1999). Bone marrow and peripheral blood dendritic cells from patients with multiple myeloma are phenotypically and functionally normal despite the detection of Kaposi's sarcoma herpesvirus gene sequences. Blood 93:1487-1495.
43. Brown, R.D., et al. (2001). Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta(1) and interleukin-10. Blood 98:2992-2998.
44. Zhu, M., et al. (2001). Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells. Cancer Res. 61:3725-3734.
45. Massaia, M., et al. (1999). Idiotype vaccination in human myeloma: Generation of tumor-specific immune responses after high-dose chemotherapy. Blood 94:673-683.
46. Schultze, J.L., Maecker, B., Von Bergwelt-Baildon, M.S., Anderson, K.S. and Vonderheide, R.H. (2001). Tumour immunotherapy: New tools, new treatment modalities adn new T-cell antigens. Vox Saguinis 80:81-89.
47. Treon, S.P., Raje, N. and Anderson, K.C. (2000). Immunotherapeutic strategies for the treatment of plasma cell malignancies. Semin. Oncol. 27:598-613.
48. Wen, Y.J., Min, R., Tricot, G., Barlogie, B., and Yi, Q. (2002). Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: Promising effector cells for immunotherapy. Blood 99:3280-3285.
49. Fong, L., Brockstedt, D., Benike, C., Wu, L. and Engleman, E.G. (2001). Dendritic cells injected via different routes induce immunity in cancer patients. J. Immunol. 166:4254-4259.
50. Yi, Q., Desikan, R., Barlogie, B., and Munshi, N. (2002) Optimizing dendritic cell-based immunotherapy in multiple myeloma. Br. J. Haematol. 117:297-305.
51. Mariani, S., et al. (2001). Severe and long-lasting disruption of T-cell receptor diversity in human myeloma after high-dose chemotherapy and autologous peripheral blood progenitor cell infusion. Br. J. Haematol. 113:1051-1059.
52. Becker, C., et al. (2001). Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay. Nat. Med. 7:1159-1162.